Acurastem Enters Into A License Agreement With Takeda To Advance Pikfyve Therapeutics; Takeda Will Receive An Exclusive, Worldwide License To Acurastem's Pikfyve Program; Acurastem To Get Upfront And Milestone Payments Totaling Up To ~$580M
Portfolio Pulse from Benzinga Newsdesk
Acurastem has entered into a license agreement with Takeda, granting Takeda an exclusive, worldwide license to Acurastem's Pikfyve program. In return, Acurastem will receive upfront and milestone payments totaling up to approximately $580 million.
September 25, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Takeda has acquired an exclusive, worldwide license to Acurastem's Pikfyve program, potentially strengthening its product portfolio.
The acquisition of the Pikfyve program could potentially strengthen Takeda's product portfolio and provide a new revenue stream. The impact on the stock price will depend on the success of the program and the market's perception of the deal.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100